Influence of immunomodulatory drugs on the gut microbiota
| Autor: | Inessa Cohen, Erin E. Longbrake, William Ruff |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine medicine.medical_treatment Adaptive Immunity Gut flora Article Immunomodulation Translational Research Biomedical Efficacy 03 medical and health sciences Sex Factors 0302 clinical medicine Immune system Physiology (medical) medicine Humans Immunologic Factors Lymphocytes Microbiome Immune Checkpoint Inhibitors Immunity Mucosal Cell Proliferation Host Microbial Interactions biology business.industry Biochemistry (medical) Models Immunological Public Health Environmental and Occupational Health Human microbiome Cancer General Medicine Immunotherapy medicine.disease biology.organism_classification Immunity Innate Gastrointestinal Microbiome 030104 developmental biology Cytokine 030220 oncology & carcinogenesis Immunology Cytokines Female business |
| Zdroj: | Transl Res |
| ISSN: | 1931-5244 |
| DOI: | 10.1016/j.trsl.2021.01.009 |
| Popis: | Immunomodulatory medications are a mainstay of treatment for autoimmune diseases and malignancies. In addition to their direct effects on immune cells, these medications also impact the gut microbiota. Drug-induced shifts in commensal microbes can lead to indirect but important changes in the immune response. We performed a comprehensive literature search focusing on immunotherapy/microbe interactions. Immunotherapies were categorized into five subtypes based on their mechanisms of action: cell trafficking inhibitors, immune checkpoint inhibitors, immunomodulators, anti-proliferative drugs, and inflammatory cytokine inhibitors. Although no consistent relationships were observed between types of immunotherapy and microbiota, most immunotherapies were associated with shifts in specific colonizing bacterial taxa. The relationships between colonizing microbes and drug efficacy were not well-studied for autoimmune diseases. In contrast, the efficacy of immune checkpoint inhibitors for cancer was tied to the baseline composition of the gut microbiota. There was a paucity of high-quality data; existing data were generated using heterogeneous sampling and analytic techniques, and most studies involved small numbers of participants. Further work is needed to elucidate the extent and clinical significance of immunotherapy effects on the human microbiome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect